© 2003 BMJ Publishing Group & Royal College of Paediatrics and Child Health
ORIGINAL ARTICLE
Fosfomycin for the initial treatment of acute haematogenous osteomyelitis
1 Division of Infectious Diseases, University Childrens Hospital of Zurich, Zurich, Switzerland
2 Department of Paediatrics, University Childrens Hospital of Zurich
3 Department of Paediatric Surgery, University Childrens Hospital of Zurich
Correspondence to:
Correspondence to:
Dr D Nadal, Division of Infectious Diseases, University Childrens Hospital of Zurich, Steinwiesstrasse 75, CH-8032 Zurich, Switzerland;
david.nadal{at}kispi.unizh.ch
Background and Aims: At our institution there has been a dichotomous antimicrobial treatment behaviour for acute haematogenous osteomyelitis (AHOM) since 1984. The surgical department favoured fosfomycin as initial choice and the medical department ß lactams. We aimed to compare the performance of both strategies.
Methods: Data from patients discharged with the diagnosis of AHOM between January 1984 and January 1998 were gathered from the charts by means of a questionnaire. Patients receiving fosfomycin treatment (FT) were compared with those receiving fosfomycin plus other antimicrobials (FT+) and those receiving no fosfomycin treatment (NFT).
Results: A total of 103 patients aged 0.115.5 years (mean 6.5, median 6.9) with AHOM received no surgical treatment initially. In 23 (22.3%) FT was instilled initially, in 47 (45.6%) FT+, and in 33 (32.0%) NFT. The pathogen was established in 30%, 36%, and 42% of FT, FT+, and NFT patients, respectively, Staphylococcus aureus being the predominant isolate. Mean C reactive protein levels and erythrocyte sedimentation rates normalised in all treatment groups after two and four weeks, respectively. The mean duration of intravenous antimicrobial treatment in FT patients was 2.5 weeks, in FT+ patients 3.1 weeks, and in NFT patients 3.8 weeks (p < 0.05), whereas the mean duration of intravenous plus oral treatment was comparable (7.1 v 6.8 v 6.5 weeks).
Conclusions: The leucocyte penetrating fosfomycin performed similarly to extracellular ß lactams in the treatment of AHOM. Intravenous treatment for longer than 2.5 weeks offered no advantage.
Keywords: acute haematogenous osteomyelitis; fosfomycin; ß lactams
Abbreviations: AHOM, acute haematogenous osteomyelitis; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; FT, fosfomycin treatment; FT+, fosfomycin plus other antimicrobials; NFT, no fosfomycin treatment
Read all eLetters![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
eLetters:
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



